Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA 4484 (miR-4484)
- Target
- miR-4484
- Molecular classification
- MicroRNA (miRNA), Non-coding RNA
01
Overview
microRNA 4484 (miR-4484) is a non-coding RNA molecule consisting of 83 nucleotides, situated on chromosome 10q26.2. It is strongly upregulated in the serum of patients with systemic sclerosis and has roles in regulating fibrosis-related genes, including those involved in collagen synthesis, metalloproteinase activity, and the TGF-β and Wnt/β-catenin signaling pathways. miR-4484 is implicated in both rheumatologic and oncologic disease processes as a post-transcriptional regulator, with suggested utility as a disease biomarker—with ongoing research into its full functional and clinical relevance[1][2].
- Other names
- hsa-mir-4484mir-4484MIR4484
02
Mechanism of action
Not applicable for traditional drugs. For oligonucleotide-based therapeutics, the mechanism would be antisense inhibition or miRNA mimic/antagomir action to alter gene expression pathways
03
Biological functions
Post-transcriptional regulation of gene expression by binding to complementary mRNA sequences, repressing translation or leading to mRNA degradationRegulation of fibrosis-related genesModulation of extracellular matrix (ECM) organizationInvolvement in major signaling pathways including TGF-β, Wnt/β-catenin, Hippo, and ErbB signalingRegulation of collagen and metalloproteinase expression
04
Disease associations
Systemic sclerosis (SSc), especially with fibrotic involvementCancer (including breast cancer, glioblastoma, diffuse large B-cell lymphoma)Oral lichen planusInterstitial lung disease (conflicting expression reports in lung tissue)
05
Safety considerations
Potential challenges in specificity for therapeutic modulation, as miRNAs can regulate multiple transcripts and pathwaysRisk of off-target effects when using miRNA-based therapiesNeed for further validation in clinical populations due to conflicting data on its expression in tissues and fluids
06
Biomarkers
miR-4484 itself is proposed as a serum biomarker for systemic sclerosis (associated with fibrosis)It may also associate with disease severity or activity, especially fibrosis and lung involvement
Beyond the preview
Go deeper on microRNA 4484 (miR-4484).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on microRNA 4484 (miR-4484).